Geron (GERN) Non-Current Assets (2010 - 2026)
Geron (GERN) posted Non-Current Assets of $35.6 million for Q1 2026, down 29.2% sequentially from $50.3 million in Q4 2025, and down 46.63% YoY from $66.7 million in Q1 2025.
Geron (GERN) Non-Current Assets (2010 - 2026) Analysis & Trends
Geron has reported Non-Current Assets for 17 years, with the latest figure at $35.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 46.63% year-over-year to $35.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $180.5 million (down 38.28% YoY) and the FY2025 annual result came in at $50.3 million, down 51.09% from the prior year.
- Non-Current Assets fell to $35.6 million in Q1 2026 per GERN's latest filing, from $50.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $102.8 million in Q4 2024 and troughed at $10.3 million in Q4 2022.
- A 5-year average of $45.0 million and a median of $45.0 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets tumbled 78.82% in 2022, then surged 639.67% in 2023.
- Over 5 years, Non-Current Assets stood at $10.3 million in 2022, then jumped by 410.49% to $52.7 million in 2023, then jumped by 94.94% to $102.8 million in 2024, then slumped by 51.09% to $50.3 million in 2025, then decreased by 29.2% to $35.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $35.6 million, $50.3 million, and $45.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 18.06 Bn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 32.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.67 Mn |
| Mar 31, 2026 | 35.59 Mn |
| Dec 31, 2025 | 50.27 Mn |
| Sep 30, 2025 | 45.04 Mn |
| Jun 30, 2025 | 49.60 Mn |
| Mar 31, 2025 | 66.68 Mn |
| Dec 31, 2024 | 102.79 Mn |
| Sep 30, 2024 | 46.89 Mn |
| Jun 30, 2024 | 76.09 Mn |
| Mar 31, 2024 | 30.57 Mn |
| Dec 31, 2023 | 52.73 Mn |
| Sep 30, 2023 | 77.93 Mn |
| Jun 30, 2023 | 38.02 Mn |
| Mar 31, 2023 | 37.85 Mn |
| Dec 31, 2022 | 10.33 Mn |
| Sep 30, 2022 | 10.54 Mn |
| Jun 30, 2022 | 10.79 Mn |
| Mar 31, 2022 | 22.50 Mn |
| Dec 31, 2021 | 38.83 Mn |
| Sep 30, 2021 | 49.74 Mn |